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The feasibility of combination irinotecan, carboplatin and docetaxel chemotherapy as first-line treatment for advanced epithelial
ovarian carcinoma was assessed. One hundred patients were randomised to receive four 3-weekly cycles of carboplatin (area under
the curve (AUC) 7) followed by four 3-weekly cycles of docetaxel 100mgm
 2 (arm A, n¼51) or docetaxel 60mgm
 2 with
irinotecan 200mgm
 2 (arm B, n¼49). Neither arm met the formal feasibility criterion of an eight-cycle treatment completion rate
that was statistically greater than 60% (arm A 71% (90% confidence interval (CI) 58–81%; P¼0.079; arm B 67% (90% CI 55–78%;
P¼0.184)). Median-dose intensities were 485% of planned dose for all agents. In arms A and B, 15.6 and 12.2% of patients,
respectively, withdrew owing to treatment-related toxicity. Grade 3–4 sensory neurotoxicity was more common in arm A (1.9 vs
0%) and grade 3–4 diarrhoea was more common in arm B (0.6 vs 3.5%). Of patients with radiologically evaluable disease at baseline,
50 and 48% responded to therapy in arms A and B, respectively; at median 17.1 months’ follow-up, median progression-free survival
was 17.1 and 15.9 months, respectively. Although both arms just failed to meet the formal statistical feasibility criteria, the observed
completion rates of around 70% were reasonable. The addition of irinotecan to first-line carboplatin and docetaxel chemotherapy
was generally well tolerated although associated with increased gastrointestinal toxicity. Further exploratory studies of
topoisomerase-I inhibitors in this setting may be warranted.
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Ovarian cancer is the fourth most commonly occurring cancer in
women, with most patients presenting with extra-pelvic disease
spread. Treatment of this advanced disease (International Federa-
tion of Gynecologic Oncology (FIGO) stage III–IV) involves
cytoreductive surgery followed by chemotherapy. Based on the
results of the pivotal GOG-111 and OV-10 studies, which
demonstrated a survival advantage for cisplatin–paclitaxel over
cisplatin–cyclophosphamide (McGuire et al, 1996; Piccart et al,
2000), first-line chemotherapy usually includes a platinum agent
plus paclitaxel. However, median survival in these studies was
only 3 years and an estimated 130000 deaths per year still occur
from ovarian cancer worldwide (Shibuya et al, 2002). Paclitaxel
treatment is also associated with peripheral neuropathy (Guastalla
and Dieras, 2003). Notably, the second-generation taxane docetaxel
in combination with carboplatin is as effective as carboplatin–
paclitaxel for first-line therapy (Vasey et al, 2004), with
myelosuppression rather than peripheral neuropathy being the
predominant toxicity.
One method for improving outcomes may be to incorporate a
third cytotoxic agent into first-line therapy – specifically, a new
potentially non-cross-resistant agent with demonstrated activity in
relapsed disease. Promising agents include the topoisomerase-I
inhibitors topotecan and irinotecan, which are active in platinum-
resistant ovarian cancer (Takeuchi et al, 1991; Gordon et al, 2001;
Bodurka et al, 2003). Irinotecan has also exhibited activity in
combination with docetaxel at a recommended 3-weekly dose of
irinotecan 200mgm
 2 and docetaxel 60mgm
 2 (Ma ¨enpa ¨a ¨ et al,
1998). A response rate of 63% was reported with docetaxel–
irinotecan treatment for recurrent disease (Ma ¨enpa ¨a ¨ et al, 2002);
the predominant toxicities were neutropenia and diarrhoea
(Ma ¨enpa ¨a ¨ et al, 1998, 2002).
The use of triplet cytotoxic combinations, however, can be com-
plicated by significant toxicity – in particular, myelosuppression,
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swhich impacts on dose intensity. One means of circumventing this
is to administer agents sequentially, as has been performed
successfully in the adjuvant treatment of breast cancer (Bonadonna
et al, 1995). The results of the GOG-132 study suggest that such an
approach could also be used in ovarian cancer (Muggia et al,
2000). In that trial, chemonaı ¨ve patients with advanced ovarian
cancer received either combination cisplatin–paclitaxel or each of
these drugs alone. However, as many patients receiving single-
agent therapy were subsequently crossed-over to the other drug
before clinical evidence of disease progression, they were
essentially receiving sequential therapy. No survival differences
were detected between the three arms, suggesting that sequential
therapy is as effective as the concurrent approach.
Laboratory data also indicate that sequential therapy may be
appropriate using platinum and taxane drugs. For instance, cell
lines with p53 mutations are hypersensitive to paclitaxel but
resistant to platinum, whereas cells with normal p53 function are
platinum sensitive (Wahl et al, 1996). Hence, initial platinum
treatment might eradicate a population of wild-type p53 tumour
cells, leaving a population of predominantly mutant p53 cells
that are amenable to subsequent treatment with taxanes. Thus,
sequential administration of optimal doses of individual agents
may allow maximum impact on distinct chemosensitive cell
populations, while avoiding the toxicity problems commonly
associated with concurrent combination chemotherapy.
This study investigated the feasibility of sequential carboplatin
followed by docetaxel or docetaxel–irinotecan as first-line therapy
in patients with FIGO stage Ic–IV epithelial ovarian, fallopian tube
or primary peritoneal carcinomas.
PATIENTS AND METHODS
Patient population
Eligible patients were women aged X18 years with a histopatho-
logical diagnosis of invasive epithelial ovarian carcinoma (EOC),
fallopian tube cancer or ovarian-type primary peritoneal cancer.
Other inclusion criteria were as follows: FIGO disease stage Ic–IV
(stage Ic patients were limited to those with malignant cells
in ascitic fluid, peritoneal washings or with tumour on the surface
of the ovary); Eastern Cooperative Oncology Group perfor-
mance status of 0–2; no prior chemotherapy or radiotherapy;
adequate bone marrow (neutrophils 41.5 10
9l
 1 or platelets
4100 10
9l
 1, haemoglobin 49.0gdl
 1), renal (serum creatinine
o1.25 upper limit of normal (ULN)) and hepatic function
(bilirubin o1 ULN, aspartate aminotransferase/alanine amino-
transferase o1.5 ULN and alkaline phosphatase o2.5 ULN).
Exclusion criteria included the following: borderline or mixed
mesodermal tumours; previous or concurrent malignancy within
the preceding 5 years (except curatively treated uterine cervical
carcinoma in situ or basal cell skin carcinoma); concurrent
severe and/or uncontrolled comorbidities; prior serious allergic
reactions; ongoing bowel obstruction or current inflammatory
bowel disease or chronic diarrhoea; pregnancy or lactation;
symptomatic peripheral neuropathy Xgrade 2. A maximum of 8
weeks was permitted between initial surgery and starting trial
chemotherapy.
All patients gave written informed consent. The trial was
approved by the Manchester Ethics Committee and by the local
ethics committees of the other participating hospitals.
Treatment
All patients initially received four cycles of carboplatin AUC 7
(AUC¼area under the curve, calculated using the Calvert formula
(Calvert et al, 1989) where the glomerular filtration rate (GFR) was
measured using an isotopic method). Carboplatin was infused over
1h in 500ml of 5% dextrose every 3 weeks. After carboplatin
initiation treatment, arm A patients received docetaxel 100mgm
 2
(1-h infusion) every 3 weeks for four cycles and arm B patients
received docetaxel 60mgm
 2 (1-h infusion) followed X30min
later by irinotecan 200mgm
 2 (30-min infusion) every 3 weeks for
four cycles.
Docetaxel premedication comprised 8mg oral dexamethasone
twice daily for 3 days, commencing 24h before docetaxel
administration in both arms. No specific premedication for
irinotecan was given. If symptoms suggestive of an acute
cholinergic syndrome developed during treatment, atropine
(0.25mg subcutaneous) was recommended and given prophylacti-
cally with subsequent cycles. High-dose loperamide was adminis-
tered for delayed diarrhoea and fluoroquinolone antibiotics if
diarrhoea occurred in the context of fever or grade 3–4
neutropenia.
Dose and schedule modification
On each scheduled treatment day, full doses of all drug(s) were
administered only if neutrophils were X1.5 10
9l
 1 and platelets
X100 10
9l
 1; otherwise, a treatment delay of r2 weeks was
permissible. Haematological recovery after 1 week resulted in the
full dose being given at the next treatment cycle. If treatment was
delayed by 41 week, or was complicated by neutropenic fever or
grade 4 thrombocytopenia, the dose was reduced to dose level –1
(Table 1). Recurrence of significant haematological toxicity with
subsequent cycles resulted in a further reduction to dose level –2.
A delay of 42 weeks for haematological recovery or further
significant haematological toxicity after two dose reductions
necessitated patient withdrawal from the study.
Prophylactic oral antibiotics were administered with subsequent
cycles in patients with grade 4 neutropenia accompanied by a
single oral temperature of 438.51C. Routine use of haematopoietic
growth factors was not recommended. If serum creatinine
increased to 41.25 ULN with carboplatin, the GFR was
remeasured. A fall in GFR of 425% from baseline resulted in
patient withdrawal from protocol therapy. The development of
grade 3–4 mucositis or hepatic toxicity during docetaxel
chemotherapy necessitated treatment delay until resolution of
toxicity to ograde 2 and subsequent cycles were administered at
dose level –1.
For patients receiving irinotecan, the occurrence of grade 3–4
diarrhoea (despite appropriate management) led to a 25% dose
reduction of irinotecan with subsequent cycles. If significant
diarrhoea recurred, the docetaxel dose was also reduced by 25%
and treatment was discontinued if this toxicity still persisted. All
Table 1 Dose levels after reduction for toxicity
Study arm Dose level 0 Dose level 1 Dose level 2
Carboplatin AUC 7 AUC 6 AUC 5
Docetaxel (arm A) 100mgm
 2 75mgm
 2 60mgm
 2
Docetaxel–irinotecan (arm B) Docetaxel: 60mgm
 2; irinotecan: 200mgm
 2 25% reduction with both drugs Further 25% reduction with both drugs
AUC¼area under the curve.
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spatients experiencing grade 3–4 neurotoxicity or significant
cardiac toxicity were withdrawn from treatment.
Clinical assessments
A full clinical examination (including pelvic examination) and
electrocardiography were performed at baseline. Clinical examina-
tion was repeated before each treatment cycle. Laboratory
investigations at baseline incorporated a full blood count (FBC;
including differential white cell count), full biochemical profile and
CA-125. The FBC and full biochemical profile were repeated on the
day of chemotherapy administration during carboplatin chemo-
therapy, and weekly during docetaxel-based chemotherapy. CA-125
measurement was repeated with each treatment cycle.
Disease extent at baseline was established by abdominopelvic
computed tomography (CT) scan and chest radiograph. Radio-
logical assessment was repeated after cycles 4 and 8 if evaluable
disease was present on baseline imaging or if there was clinical or
CA-125 evidence of disease progression. If interval debulking was
performed after carboplatin chemotherapy, repeat imaging was
required before starting docetaxel-containing chemotherapy.
Disease response was assessed using modified Southwest Oncology
Group criteria. Patients with disease progression after completing
the carboplatin phase proceeded to the docetaxel-based treatment
phase (unless the treating clinician deemed this inappropriate).
Patient quality of life (QoL) was assessed at baseline using the
European Organisation for Research and Treatment of Cancer
(EORTC) core questionnaire QLQ-C30 combined with ovarian
cancer module QLQ-OV28. These questionnaires were repeated
after completion of carboplatin treatment and before each
docetaxel-based chemotherapy cycle. Toxicities were documented
throughout chemotherapy using the National Cancer Institute of
Canada Expanded Common Toxicity Criteria (version 2.0).
Patient follow-up – including full clinical and pelvic examina-
tions, serum CA-125 measurement and QoL assessment – was
performed every 2 months until disease progression or for a
maximum of 2 years. Abdominopelvic CT scan was performed if
progressive disease was suspected.
Statistical considerations
This was a multicentre, prospective, two-arm, randomised phase II
feasibility study. Treatment allocation was performed by mini-
misation with stratification for centre, FIGO stage, performance
status and residual disease. The primary end point was the
percentage of patients completing eight cycles of chemotherapy:
80% was deemed to be clearly acceptable, 60–80% a ‘grey area’ and
o60% clearly unacceptable. The study was designed to test the
null hypothesis that the completion rate was p60% against the
alternative of 460% using Fleming’s test (Fleming, 1982). Setting a
one-sided significance level of 5% and a power of 90% for a true
completion rate of 80% required 44 patients to be recruited to each
arm.
The study was not powered to detect differences in efficacy
between the three arms; randomisation was utilised to ensure that
patients with similar characteristics entered each arm. However, it
also permitted a preliminary analysis to be made of the range of
efficacy to be expected.
Exploratory comparisons of patient characteristics and treat-
ment outcomes between the two arms were carried out using the w
2
test and Fisher’s exact test.
RESULTS
Patients
Between June 2001 and September 2002, 100 patients (51 in arm A,
49 in arm B) were recruited from 17 European centres.
Demographic characteristics were similar in both groups (Table 2).
Most (81%) patients had FIGO stage III–IV disease and 42%
had bulky residual disease (42cm diameter) after surgery. The
most common histological subtype was serous adenocarcinoma
and 64% of tumours were moderately or poorly differentiated.
Although more patients in arm A were of performance status 0,
this difference was not statistically significant (w
2¼3.39,
P¼0.066). Two patients who commenced therapy were subse-
quently withdrawn owing to incorrect histological diagnosis (one
mixed mullerian tumour, one metastatic carcinoid). These patients
were included in the toxicity and dose intensity analyses, but
excluded from efficacy assessments.
Chemotherapy administration and dose intensity
A summary diagram indicating the progress of the two patient
cohorts through treatment is given in Figure 1.
All patients received X1 cycle of carboplatin AUC 7 and 88 out
of 100 patients completed carboplatin therapy. Seventy-seven of
379 carboplatin cycles (20.3%) were delayed by X1 week and 27
cycles were subsequently given at reduced dose. The majority
(87%) of the delays were due to haematological toxicity. The
median carboplatin dose intensity achieved was 91.7% of the
planned dose in arm A and 85.9% in arm B.
Forty-three patients (84%) in arm A commenced docetaxel
chemotherapy and 36 (71%; 90% confidence interval (CI) 58–81%)
completed all planned therapy (primary end point). Nineteen
initial cycles of docetaxel were delayed owing to carboplatin-
induced haematological toxicity. In contrast, only six subsequent
cycles were delayed by X1 week and, although 14 cycles were
dose-reduced (primarily owing to neutropenic fever), the median-
dose intensity achieved was 97.7%. Thirty-eight patients (78%) in
arm B commenced docetaxel–irinotecan treatment and 33 (67%;
90% CI 55–78%) completed planned therapy (primary end point).
Fifteen initial cycles were delayed owing to carboplatin-related
toxicity. Twelve subsequent cycles were delayed and 17 given at
reduced dose (overall, nine cycles were dose-reduced owing to
neutropenic fever and seven owing to gastrointestinal toxicity
(primarily diarrhoea)). Of the planned dose, the median-dose
intensity was 92.6% for docetaxel and 92.4% for irinotecan.
Table 2 Patient demographics
Age Arm A (n¼51) Arm B (n¼49)
Median 56 60
Range 31–72 41–76
Performance status No. of patients % No. of patients %
0 39 76.5 28 57.1
1 11 21.6 21 42.9
2 1 1.9 0 0
FIGO stage
Ic 4 7.8 0 0
II 7 13.7 8 16.3
III 37 72.6 36 73.5
IV 3 5.9 5 10.2
Residual disease
None/micro 13 25.5 13 26.5
p2cm 17 33.3 15 30.6
42cm 21 41.2 21 42.9
Histological subtype
Serous/papillary 24 47.1 28 57.1
Mucinous 4 7.8 2 4.1
Clear cell 3 5.9 3 6.1
Endometrioid 5 9.8 5 10.2
Other 12 23.5 9 18.3
Not known 3 5.9 2 4.1
FIGO¼International Federation of Gynecologic Oncology.
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sNeither arm demonstrated a treatment completion rate statis-
tically greater than 60%, which was the predefined feasibility
criterion.
Toxicity
The predominant toxicities reported were haematological (Table 3).
As no significant toxicity differences were noted between arms A
and B during the carboplatin treatment phase, these data were
combined: 10.8% of carboplatin cycles were complicated by grade
3–4 neutropenia and 8.2% by grade 3–4 thrombocytopenia.
However, only 2.1% of cycles were complicated by neutropenic
fever and 1.1% by thrombocytopenia-related bleeding. Apart from
vomiting (grade 3–4 in 5.8% of cycles), non-haematological
toxicities were generally mild throughout carboplatin treatment.
During the docetaxel-based treatment phase, differences in
toxicity profile were evident between the two arms. Grade 3–4
neutropenia was reported in 63.5 and 50.2% of cycles in arms A
and B, respectively; neutropenic fever complicated 7.5 and 5.7% of
cycles, respectively. The incidences of other haematological
toxicities were low in both arms. Gastrointestinal toxicity was
more common in arm B, with grade 3–4 diarrhoea seen in 3.5% of
cycles compared with only 0.6% in arm A. Sensory neurotoxicity
was reported more frequently in arm A, consistent with the higher
docetaxel dose; 5.0% of cycles in arm A vs 1.4% in arm B were
complicated by grade 2–4 sensory neuropathy (1.9 vs 0% by grade
3–4 sensory neuropathy). The differences in toxicity were reflected
in the reasons for dose reduction or delay noted above. Grade 2
alopecia was reported in 43.7 and 50.4% of cycles in arms A and B,
respectively. Overall, 14 patients (eight in arm A, six in arm B)
discontinued protocol treatment because of toxicity; the reasons
are listed in Table 4.
Two deaths due to adverse events were reported (both in arm B):
one patient died from enterococcal septicaemia and pneumonia
4 cycles carboplatin AUC 7 
Arm A
(n=51)
Radiological assessment + interval debulking if prespecified 
Arm A
4 cycles docetaxel
100 mg m–2 
(n=43)
Arm B
4 cycles docetaxel
60 mg m–2 +
irinotecan 200 mg m–2
(n=38)
3 Toxicity 
3 Progression
5 Other 
Arm A
Therapy completion
(n=36)
4 Toxicity 
2 Progression
1 Other 
3 Toxicity (1 death)
0 Progression 
2 Other 
Patients assessed as eligible and randomised (n=100)
4 Toxicity 
3 Progression 
1 Other
Arm B
(n=49)
Arm B
Therapy completion
(n=33)
Figure 1 Flow chart indicating progress of the two patient cohorts through Arms A and B. All chemotherapy cycles were administered at 3-weekly
intervals. Numbers of patients (n) at each stage of therapy are listed. Reasons for discontinuation are given in italics.
Table 3 Percentage of cycles of chemotherapy complicated by toxicity
Docetaxel 7 irinotecan
Carboplatin Arm A Arm B
No. of cycles
379 161 141
Grade 3 43434
Haematological toxicity
Neutropenia 8.6 2.2 22.3 41.2 25.2 25.0
Anaemia 4.1 0.5 0 0.7 0 0
Thrombocytopenia 5.5 2.7 0 0 0.8 0.8
Gastrointestinal
Nausea 1.1 — 0.6 — 2.8 —
Vomiting 4.7 1.1 1.9 0 1.4 0
Diarrhoea 1.1 0.3 0.6 0 2.8 0.7
Constipation 0.8 0 0 0 0.7 0
Abdominal pain 1.3 0 0 0 0.7 0.7
Neurological
Sensory 0.3 0 1.9 0 0 0
Motor 0 0 0 0 0 0
Other
Oedema 0.3 0 0 0 0 0
Dyspnoea 0.3 0.3 0 0 0 0
Stomatitis 0.5 0 0.6 0 0 0
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sassociated with grade 4 neutropenia 5 days after receiving
docetaxel and irinotecan and one patient died from secondary
complications due to a treatment-unrelated ischaemic stroke
suffered during the carboplatin treatment phase. At the time of
death, this latter patient had discontinued protocol treatment
owing to disease progression.
Efficacy
At baseline, 30 patients in arm A and 25 in arm B had
radiologically evaluable disease. Of these, 17 (57%) in arm A
achieved a disease response after the carboplatin phase, compared
with 12 (48%) in arm B (Table 5). After completion of docetaxel-
based treatment, seven patients (23%) in arm A had achieved a
complete response and eight (27%) had achieved a partial
response; seven (23%) patients had disease progression. In arm
B, two patients (8%) achieved a complete response and 10 (40%)
achieved a partial response; seven (28%) patients had disease
progression.
The change in cytotoxic agents after the first four cycles allowed
a preliminary assessment of the relative efficacies of docetaxel vs
docetaxel–irinotecan in improving disease status. Of the 22
patients in arm A and 19 patients in arm B with partial response
or stable disease after carboplatin initiation therapy, six (27%) had
improved radiological findings after docetaxel (arm A) compared
with three (16%) after docetaxel–irinotecan (arm B) (odds
ratio¼0.5; 95% CI 0.147–1.702). Disease progression was seen
in three (14%) docetaxel patients and three (16%) docetaxel–
irinotecan patients.
Although nine patients (9%) had disease progression after
carboplatin, only three (3%) remained on protocol. Only one of
these patients (arm B) responded to further therapy. Of the
patients with radiologically unevaluable disease at trial entry, two
patients (one in each arm) experienced disease progression during
docetaxel-based therapy.
Sixty-one patients (61%) had disease that could be assessed for
CA-125 response using the Gynecologic Cancer Intergroup (GCIG)
criteria (Rustin et al, 2004). Forty-one of these patients (67%)
met the criteria for response, 33 of whom had radiologically
measurable disease. Of these patients, 27 had a radiological
disease response, five had stable disease and one had radiological
disease progression. Of the patients whose CA-125 failed to
respond to therapy and who had radiologically measurable disease
(11 patients), three had a disease response on cross-sectional
imaging.
The median follow-up period was 17.1 months, during which
time 49 patients (50%) experienced disease progression. Median
progression-free survival was 17.1 months in arm A (95% CI 11.7–
22.4 months) and 15.9 months in arm B (95% CI 8.0–23.9
months).
Quality of life
Of the eligible patients, 82% completed the QoL questionnaires
at baseline (77% after four cycles and 71% after eight cycles).
However, only 42% of eligible patients completed questionnaires at
the first post-treatment follow-up. No significant differences were
seen between the two arms in overall change in QoL or change in
any symptom-specific subscales.
DISCUSSION
This randomised phase II study assessed the feasibility of
delivering sequential schedules of carboplatin, docetaxel and
irinotecan as first-line therapy in advanced EOC. One hundred
patients were randomised to receive four 3-weekly cycles of either
docetaxel 100mgm
 2 (arm A) or docetaxel 60mgm
 2 and
irinotecan 200mgm
 2 (arm B) after four cycles of carboplatin at
a dose of AUC 7 every 3 weeks. Both arms just failed to meet the
predefined feasibility criterion of a treatment completion rate
statistically greater than 60% (arm A 71%, 90% CI 58–81%,
P¼0.079; arm B 67%, 90% CI 55–78%, P¼0.184).
The overall response rates achieved in patients with radiologi-
cally evaluable disease of 50% in arm A and 48% in arm B appear
modest for a phase II study in this patient group, despite a median
dose intensity of 485% for all drugs administered. The results,
however, are consistent with the 58.7% achieved with carboplatin–
docetaxel in the SCOTROC I trial on which this study was based
(Vasey et al, 2004). Importantly, the median progression-free
survival figures of 17.1 and 15.9 months in arms A and B,
respectively, are also similar to those previously reported in phase
II and III studies of first-line chemotherapy in patients with
Table 4 Reasons for treatment discontinuation
Arm A Arm B
Cycle
No. of patients
completed Toxicity Progression Consent Other
No. of patients
completed Toxicity Progression Consent Other
15 1 — — — — 4 9 — — — —
2 4 9 110 04 8 100 0
3 4 8 210 04 6 210 0
4 4 5 420 04 3 321 0
5 4 3 431 03 8 332 3
6 4 2 531 03 5 434 3
7 4 0 551 03 5 434 3
8 3 6 851 13 3 634 3
Table 5 Radiological response assessment in patients with evaluable
disease at trial entry
Arm A (n¼30) Arm B (n¼25)
Post-carboplatin Overall Post-carboplatin Overall
CR 3 (10) 7 (23) 0 (0) 2 (8)
PR 14 (47) 8 (27) 12 (48) 10 (40)
CR + PR 17 (57) 15 (50) 12 (48) 12 (48)
SD 8 (27) 5 (17) 7 (28) 4 (16)
PD 4 (13) 7 (23) 5 (20) 7 (28)
Measurable disease
a 1 (3) 3 (10) 1 (4) 2 (8)
Non-evaluable 20 (—) 23 (—)
aFailed to complete therapy. Values in parentheses are percentages given as the
proportion of patients with radiologically evaluable disease at trial entry.
CR¼complete response; PD¼progressive disease; PR¼partial response;
SD¼stable disease.
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spredominantly stage III–IV EOC (International Collaborative
Ovarian Neoplasm Group, 2002; Guppy et al, 2004; Harries et al,
2004; Vasey et al, 2004), providing preliminary evidence that the
regimens we tested have efficacy consistent with current first-line
therapies.
The use of sequential therapy also allowed a preliminary
assessment of the relative efficacies of docetaxel and docetaxel–
irinotecan in improving disease status after single-agent carbo-
platin. Patients with persistent disease after carboplatin treatment
represented a cohort of patients in this trial with relatively
chemoresistant disease. In this cohort, 27% of patients receiving
docetaxel alone had improved disease status compared with 16%
of patients receiving docetaxel–irinotecan (odds ratio¼0.5; 95%
CI 0.147–1.702). These figures are consistent with equivalence
between the two treatment arms in a study of this size (Fisher’s
exact test P¼0.62). They are, however, lower than the response
rates reported in a Finnish phase II study of docetaxel–irinotecan
in relapsed EOC, which documented a response rate of 63% in both
platinum-sensitive and refractory disease (Ma ¨enpa ¨a ¨ et al, 2002).
However, Guppy et al (2004) reported decreasing response rates
for each agent in their small phase II study using sequential
carboplatin, paclitaxel and topotecan in a similar patient group to
that investigated here.
The present study did reveal differences in the toxicity profiles
of the two treatment regimens under investigation, although the
toxicities seen were, in general, predictable and manageable.
Myelosuppression was the most frequent toxicity (10.8% of
carboplatin cycles, 63.5% of docetaxel cycles and 50.2% of
docetaxel–irinotecan cycles were associated with grade 3–4
neutropenia), although the rates of complicated neutropenia were
low. Differences were also seen with non-haematological toxicity.
Significant sensory neuropathy was more common with docetaxel
alone (probably secondary to the higher docetaxel dose) whereas
serious gastrointestinal side effects were more frequent with
docetaxel–irinotecan. A total of 3.5% of cycles of combination
chemotherapy were complicated by grade III/IV diarrhoea
compared with 0.9% of those using docetaxel alone, and one
patient in arm B died of enterococcal septicaemia. While this
toxicity pattern has been reported in other phase II studies of
docetaxel–irinotecan combinations, it is generally considered
acceptable and is not affected by regimen scheduling (Kurtz
et al, 2003; Pectasides et al, 2005; Wachters et al, 2005). While such
differences were apparent using conventional toxicity scores, no
significant QoL differences emerged (either on global measures or
on the symptom-specific subscales). Although the EORTC-QLQ30
score has previously been reported to correlate well with toxicity
scores for ovarian cancer patients undergoing chemotherapy
(Butler et al, 2004), the low number of severe objective toxicities
and the relatively poor compliance with questionnaire completion
may explain the inability of this modality to detect differences in
this study.
During the carboplatin initiation phase, seven patients (7%)
withdrew owing to excessive toxicity and, subsequently, four
patients (9.3%) receiving docetaxel and three (7.9%) receiving
docetaxel–irinotecan discontinued therapy owing to toxicity,
giving a total withdrawal rate of 14%. These figures compare
favourably with those seen in a phase II study of the triplet
combination carboplatin AUC 5/paclitaxel 150mgm
 2/irinotecan
100mgm
 2 administered every 3–4 weeks, where 27% of patients
withdrew owing to toxicity (Escobar et al, 2004).
Most previous studies investigating the incorporation of
topoisomerase-I inhibitors into first-line therapy of EOC have
used triplet combinations, with subsequent difficulties in dose
escalation owing to myelotoxicity (Herben et al, 1999; Cacciari
et al, 2000; Bolis et al, 2001; Escobar et al, 2004). The results
reported here indicate the feasibility of this concept by using a
sequential approach to maintain dose intensity. In particular, a
similar total dose of carboplatin (AUC 28 vs 30) was administered
compared to standard carboplatin–paclitaxel regimens and a
higher dose intensity (AUC 2.5 vs 1.25 per week) was achieved
during the platinum phase of therapy. We also documented a
manageable toxicity profile for docetaxel–irinotecan that reduces
neurotoxicity compared to using a higher dose of docetaxel alone
although at the expense of increased diarrhoea. However, the
recent results of two randomised phase III studies (De Placido
et al, 2004; Pfisterer et al, 2005) have failed to demonstrate an
improvement in survival with the addition of four cycles of the
topoisomerase-I inhibitor topotecan after standard carboplatin–
paclitaxel as first-line treatment for EOC. Although the MITO-1
study (De Placido et al, 2004) can be criticised for only effectively
assessing the concept of consolidation therapy, as 87% of patients
randomised to topotecan or placebo had already obtained a
complete response to standard treatment, patients were rando-
mised at registration in the GINECO/AGO-OVAR trial (Pfisterer
et al, 2005) and 78% of those randomised to sequential topotecan
received this therapy.
Nevertheless, the present study suggests that further investiga-
tion of the concept of delivering sequential combinations of
carboplatin, docetaxel and irinotecan at high-dose intensity to
patients with ovarian cancer may be appropriate.
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